Jobs
View more job listings or post a job
Agios Pharmaceuticals Senior Scientist, DMPK/Clinical Pharmacology
UC Davis - California Animal Health and Food Safety Laboratory System Job Title: Analytical Chemist Payroll Title: Staff Research Associate 3 (Exempt) Salary Range:  $4592.00-$7384.00/Month Appointment Type:  Career - 100%  
Precision for Medicine Scientist - Bioanalytical Assays
Chinook Therapeutics, Inc. DMPK Discovery Lead
Boston Biomedical Inc SR/Clinical Research Scientist - Clinical Development - Oncology 
Applied Molecular Transport (AMT) Research Associate, Pharmacology/Biology
Applied Molecular Transport (AMT) Senior Scientist, Pharmacology/Biology
RAPT Therapeutics Research Associate, DMPK
Jazz Pharmaceuticals Senior Manager, Clinical Pharmacology
Post a job

Symposium

Development of Drug/Device Combinations


Speakers: Paul Feldman, Ph.D. (Intarcia Therapeutics); Deepa Deshpande, Ph.D (Universal Regulatory, Inc.); Vladimir Bantseev, Ph.D. (Genentech); Christopher Rhodes, Ph.D. (Drug Delivery Experts); James Oberhauser, Ph.D. (Gilead); Louis-Georges Guy, Ph.D. (AccelLAB); Mark Bush, Ph.D. (Nuventra)
Organizers: Doris Zane, Ph.D. (Intarcia Therapeutics)
Date: 2020-02-11
Time: 8:45-17:00 Pacific Time
Registration fee (USD): Regular: $125; Academic: $75; Students & Unemployed: $25
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor: (1)Biomere
Vendor show vendors registered to date: (6)Absorption Systems; CoreRx; Foster Delivery Science, Inc; Intertek Pharmaceutical Services; Nuventra Pharma Sciences; Viitai
Registration: http://www.PBSS.org
Registration deadline:2020-02-07  (it will close sooner if the seating cap is reached)

About the Topic

As defined by FDA, combination products are therapeutic and diagnostic products that combine drugs, devices, and/or biological products. The Agency expects to receive large numbers of combination products for review as technological advances continue to merge product types and blur the historical lines of separation between FDA’s medical product centers, which are made up of the Center for Biologics Evaluation and Research (CBER), the Center for Drug Evaluation and Research (CDER), and the Center for Devices and Radiological Health (CDRH).

As Drug/Device combination products typically involve components that would normally be regulated under different types of regulatory authorities, and frequently by different FDA Centers, they raise challenging regulatory challenges. Differences in regulatory pathways for each component can impact the regulatory processes for all aspects of product development, such as preclinical testing, marketing applications, manufacturing and quality control. This symposium will cover some of these challenges faced in the development of drug/device combination products presented by speakers from Industry, FDA and Contract Research Organizations.

 

Presentations:

  • Application of The Intarcia Medici Drug Delivery SystemTM for Long Acting HIV Prevention for Global Health - Paul Feldman, Ph.D., Head of Discovery and Translational Medicine, Intarcia Therapeutics, Inc. 
  • Drug-Device Combinations - Overview of Regulatory Landscape and Development Considerations - Deepa Deshpande, Ph.D., RAC, President, Universal Regulatory, Inc. 
  • Nonclinical toxicology strategies for Drug/device combination: PDS with ranibizumab for nvAMD as an example - Vladimir Bantseev, Ph.D., FAAO, Senior Scientist, Toxicology Therapeutic Area Lead – Ophthalmology, Safety Assessment, Genentech.
  • Exenatide and Its Life Cycle - Christopher A. Rhodes, Ph.D., President & CEO, Drug Delivery Experts. 
  • Injectable Device Solutions for Complex Formulations - James Oberhauser, Ph.D., Senior Director of Device Development and Clinical Packaging Engineering, Gilead. 
  • Preclinical evaluation of drug device combination products: particularities and challenges - Louis-Georges Guy, Ph.D., Director, Science, AccelLAB. 
  • Drug/Device Combination Products: A Pharmacokinetic Perspective - Mark Bush, Ph.D., Vice President, Clinical Pharmacology and Pharmacokinetics, Nuventra, Inc. 


2020-02-24, MS Courses by Dr. Jack Henion: Advanced LC-MS/MS (Day1) & Interpretation of MS/MS CID Spectra (Day2)
2020-03-09, Preclinical Models to Guide Therapeutic Development in Oncology
2020-03-16, Clinical Trials Essentials: An Intensive One-Week Course (register for the full week or half day sessions)
2020-04-10, Development of Multivalent Protein Conjugates as a Strategy to Engineer Drug Pharmacology
2020-04-13, Preclinical and Clinical Development of Cell-based Immunotherapies: Translational PKPD, Safety, Biomarker, CMC, Clinical Pharmacology & Clinical Trials
2020-05-12, Regulated Large Molecule Bioanalysis: Fundamentals, the New FDA Guidance and Beyond
2020-05-22, No More Undruggables: Unconventional Approaches for Drug Discovery and Design - prodrugs, PROTACS, fragment-based design, directed evolution and beyond
2020-06-23, Advances in Immuno-Oncology (A Joint Symposium by PBSS and BioScience Forum)
┬ęPharmaceutical & BioScience Society, International; Last Modified: 1/24/2020; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Hypha Discovery Experts in scalable synthesis & purification of drug metabolites, including CYP, AOX, FMO metabolites as well as O-, N-, acyl glucuronides & sulfates
ReechPharma Bay Area (Newark) company, supporting clients with CUSTOMIZED FORMULATIONS that are soluble, stable, scalable & safer. Preclinical to post-marketing!
Alturas Analytics, Inc. Expert GLP & non-GLP LC-MS/MS, GC-MS/MS bioanalytical & PK/TK analysis services of small & large molecules in any matrix. Discovery through phase IV.
Simulations Plus Intro & Advanced GastroPlus PBPK PBBM modeling workshops Feb. 24-28 in Redwood City, CA. Register today!
Pacific BioLabs Bay Area CRO with 37 years experience in Methods Development & Validation, Bioanalysis, Toxicology, Immunogenicity, Stability Studies & Microbiology
Submit a Text Ad